News Image

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Provided By GlobeNewswire

Last update: Nov 24, 2025

Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB

Read more at globenewswire.com

CERVOMED INC

NASDAQ:CRVO (11/26/2025, 1:29:53 PM)

9.68

+0.05 (+0.52%)



Find more stocks in the Stock Screener

Follow ChartMill for more